{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T06:02:22Z","timestamp":1792821742700,"version":"4.5.0"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2018,8,1]],"date-time":"2018-08-01T00:00:00Z","timestamp":1533081600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2018,8]]},"DOI":"10.1007\/s40265-018-0963-x","type":"journal-article","created":{"date-parts":[[2018,8,16]],"date-time":"2018-08-16T10:33:37Z","timestamp":1534415617000},"page":"1277-1284","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":137,"title":["Encorafenib and Binimetinib: First Global Approvals"],"prefix":"10.1007","volume":"78","author":[{"given":"Matt","family":"Shirley","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,8,16]]},"reference":[{"issue":"7","key":"963_CR1","doi-asserted-by":"publisher","first-page":"1681","DOI":"10.1016\/j.cell.2015.05.044","volume":"161","author":"Cancer Genome Atlas Network","year":"2015","unstructured":"Cancer Genome Atlas Network. Genomic classification of cutaneous melanoma. Cell. 2015;161(7):1681\u201396.","journal-title":"Cell"},{"issue":"2","key":"963_CR2","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1016\/j.pharmthera.2013.11.011","volume":"142","author":"C Hertzman Johansson","year":"2014","unstructured":"Hertzman Johansson C, Egyhazi Brage S. BRAF inhibitors in cancer therapy. Pharmacol Ther. 2014;142(2):176\u201382.","journal-title":"Pharmacol Ther"},{"key":"963_CR3","unstructured":"National Comprehensive Cancer Network\u00ae. NCCN clinical practice guideline in oncology (NCCN Guidelines\u00ae)\u2014melanoma (version 3.2018). 2018. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/melanoma.pdf . Accessed 20 Jul 2018."},{"key":"963_CR4","unstructured":"US FDA. Braftovi\u2122 (encorafenib) capsules: US prescribing information. 2018. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/210496lbl.pdf . Accessed 20 Jul 2018."},{"key":"963_CR5","unstructured":"US FDA. Mektovi\u00ae (binimetinib) tablets: US prescribing information. 2018. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/210498lbl.pdf . Accessed 20 Jul 2018."},{"issue":"5","key":"963_CR6","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1016\/S1470-2045(18)30142-6","volume":"19","author":"R Dummer","year":"2018","unstructured":"Dummer R, Ascierto PA, Gogas HJ, et al. Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 2018;19(5):603\u201315.","journal-title":"Lancet Oncol"},{"key":"963_CR7","unstructured":"US FDA. FDA approves encorafenib and binimetinib in combination for unresectable or metastatic melanoma with BRAF mutations. 2018. https:\/\/www.fda.gov\/drugs\/informationondrugs\/approveddrugs\/ucm611981.htm . Accessed 20 Jul 2018."},{"key":"963_CR8","unstructured":"Array BioPharma Inc. Array BioPharma submits New Drug Applications to FDA for binimetinib and encorafenib in advanced melanoma [media release]. 2017. http:\/\/investor.arraybiopharma.com\/news-releases\/news-release-details\/array-biopharma-submits-new-drug-applications-fda-binimetinib . Accessed 20 Jul 2018."},{"key":"963_CR9","unstructured":"US FDA. Orphan Drug designations and approvals. 2013. https:\/\/www.accessdata.fda.gov\/scripts\/opdlisting\/oopd\/detailedIndex.cfm?cfgridkey=411613 . Accessed 20 Jul 2018."},{"key":"963_CR10","unstructured":"European Medicines Agency. Applications for new human medicines under evaluation by the Committee for Medicinal Products for Human Use. 2017. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Report\/2017\/09\/WC500234396.pdf . Accessed 20 Jul 2018."},{"key":"963_CR11","unstructured":"Array BioPharma Inc. Encorafenib and binimetinib combination treatment demonstrates 33.6\u00a0month median overall survival (OS) in patients with BRAF-mutant melanoma in phase 3 COLUMBUS trial [media release]. 2018. http:\/\/investor.arraybiopharma.com\/news-releases\/news-release-details\/encorafenib-and-binimetinib-combination-treatment-demonstrates . Accessed 20 Jul 2018."},{"key":"963_CR12","unstructured":"Ono Pharmaceutical Co. Ltd. ONO submits applications for manufacturing and marketing approval for encorafenib, a BRAF inhibitor and binimetinib, a MEK inhibitor for indication of unresectable BRAF-mutant melanoma in Japan [media release]. 2018. http:\/\/www.ono.co.jp\/eng\/news\/pdf\/sm_cn180425.pdf . Accessed 20 Jul 2018."},{"key":"963_CR13","unstructured":"European Medicines Agency. Summary of opinion (initial authorisation): Mektovi (binimetinib). 2018. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Summary_of_opinion_-_Initial_authorisation\/human\/004579\/WC500252668.pdf . Accessed 06 Aug 2018."},{"key":"963_CR14","unstructured":"European Medicines Agency. Summary of opinion (initial authorisation): Braftovi (encorafenib). 2018. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Summary_of_opinion_-_Initial_authorisation\/human\/004580\/WC500252667.pdf . Accessed 06 Aug 2018."},{"key":"963_CR15","unstructured":"Array BioPharma Inc. Array BioPharma reports financial results for the first quarter of fiscal 2017 [media release]. 2016. http:\/\/investor.arraybiopharma.com\/news-releases\/news-release-details\/array-biopharma-reports-financial-results-first-quarter-15 . Accessed 20 Jul 2018."},{"key":"963_CR16","unstructured":"European Medicines Agency. Withdrawal of the marketing authorisation application for Balimek (binimetinib). 2018. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Medicine_QA\/2018\/01\/WC500242413.pdf . Accessed 20 Jul 2018."},{"key":"963_CR17","unstructured":"Array BioPharma Inc. Array BioPharma provides NEMO update [media release]. 2017. http:\/\/investor.arraybiopharma.com\/news-releases\/news-release-details\/array-biopharma-provides-nemo-update . Accessed 20 Jul 2018."},{"key":"963_CR18","unstructured":"Array BioPharma Inc. Array BioPharma announces decision to discontinue MILO study in ovarian cancer [media release]. 2016. http:\/\/investor.arraybiopharma.com\/news-releases\/news-release-details\/array-biopharma-announces-decision-discontinue-milo-study . Accessed 20 Jul 2018."},{"issue":"10","key":"963_CR19","doi-asserted-by":"publisher","first-page":"3347","DOI":"10.1002\/art.22869","volume":"56","author":"MJ Thiel","year":"2007","unstructured":"Thiel MJ, Schaefer CJ, Lesch ME, et al. Central role of the MEK\/ERK MAP kinase pathway in a mouse model of rheumatoid arthritis: potential proinflammatory mechanisms. Arthritis Rheum. 2007;56(10):3347\u201357.","journal-title":"Arthritis Rheum"},{"key":"963_CR20","unstructured":"Array BioPharma Inc. Array announces completion of binimetinib and encorafenib transactions [media release]. 2015. http:\/\/investor.arraybiopharma.com\/news-releases\/news-release-details\/array-announces-completion-binimetinib-and-encorafenib . Accessed 20 Jul 2018."},{"key":"963_CR21","unstructured":"Array BioPharma Inc. Array announces closing of Pierre Fabre transaction [media release]. 2015. http:\/\/investor.arraybiopharma.com\/news-releases\/news-release-details\/array-announces-closing-pierre-fabre-transaction . Accessed 20 Jul 2018."},{"key":"963_CR22","unstructured":"Array BioPharma Inc. Array BioPharma and Ono Pharmaceutical Co., Ltd. announce a license, development and commercialization partnership for two novel oncology compounds, binimetinib and encorafenib [media release]. 2017. http:\/\/investor.arraybiopharma.com\/news-releases\/news-release-details\/array-biopharma-and-ono-pharmaceutical-co-ltd-announce-license . Accessed 20 Jul 2018."},{"key":"963_CR23","unstructured":"European Medicines Agency. Assessment report: Mektovi (binimetinib). 2017. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Application_withdrawal_assessment_report\/2018\/03\/WC500246460.pdf . Accessed 06 Aug 2018."},{"issue":"15 Suppl","key":"963_CR24","doi-asserted-by":"publisher","first-page":"9504","DOI":"10.1200\/JCO.2018.36.15_suppl.9504","volume":"36","author":"R Dummer","year":"2018","unstructured":"Dummer R, Ascierto PA, Gogas H, et al. Overall survival in COLUMBUS: A phase 3 trial of encorafenib (ENCO) plus binimetinib (BINI) vs vemurafenib (VEM) or enco in BRAF-mutant melanoma. J Clin Oncol. 2018;36(15 Suppl):9504.","journal-title":"J Clin Oncol."},{"issue":"18","key":"963_CR25","doi-asserted-by":"publisher","first-page":"5339","DOI":"10.1158\/1078-0432.CCR-16-2923","volume":"23","author":"J-P Delord","year":"2017","unstructured":"Delord J-P, Robert C, Nyakas M, et al. Phase I dose-escalation and -expansion study of the BRAF inhibitor encorafenib (LGX818) in metastatic BRAF-mutant melanoma. Clin Cancer Res. 2017;23(18):5339\u201348.","journal-title":"Clin Cancer Res"},{"issue":"Suppl 5","key":"963_CR26","doi-asserted-by":"crossref","first-page":"v429","DOI":"10.1093\/annonc\/mdx377.002","volume":"28","author":"R Dummer","year":"2017","unstructured":"Dummer R, Ascierto PA, Gogas H, et al. Results of COLUMBUS Part 2: a phase 3 trial of encorafenib (ENCO) plus binimetinib (BINI) versus ENCO in BRAF-mutant melanoma. Ann Oncol. 2017;28(Suppl 5):v429\u201330.","journal-title":"Ann Oncol"},{"key":"963_CR27","unstructured":"Van Cutsem E, Cuyle P-J, Huijberts S, et al. BEACON CRC study safety lead-in: assessment of the BRAF inhibitor encorafenib\u2009+\u2009MEK inhibitor binimetinib\u2009+\u2009anti-epidermal growth factor receptor antibody cetuximab for BRAF V600E metastatic colorectal cancer. 2018. http:\/\/investor.arraybiopharma.com\/static-files\/01f7b17c-7495-4ff6-97d3-321cadf643d6 . Accessed 20 Jul 2018."}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40265-018-0963-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-018-0963-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-018-0963-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,7]],"date-time":"2020-11-07T21:21:06Z","timestamp":1604784066000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40265-018-0963-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8]]},"references-count":27,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2018,8]]}},"alternative-id":["963"],"URL":"https:\/\/doi.org\/10.1007\/s40265-018-0963-x","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,8]]},"assertion":[{"value":"16 August 2018","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"The preparation of this review was not supported by any external funding.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"During the peer review process the manufacturer of the agents under review was offered an opportunity to comment on the article. Changes resulting from any comments received were made by the author on the basis of scientific completeness and accuracy. Matt Shirley is a salaried employee of Adis\/Springer, is responsible for the article content and declares no relevant conflicts of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}